Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.48 |
| ▸ | FBP1 | P09467 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4415445 | 0.94 | CNR2 (0.44) | CNR2RIPK1TSHR | |
| SCHEMBL3799616 | 0.79 | CNR2 (0.59) | CNR2FBP1RORCTSHR | |
| SCHEMBL3800355 | 0.77 | CNR2 (0.44) | CNR2 | |
| SCHEMBL3797729 | 0.75 | CNR2 (0.45) | CNR2FBP1RORCTSHRPOLB | |
| SCHEMBL3141139 | 0.73 | CES2 (0.34) | — | |
| SCHEMBL11365709 | 0.72 | ATM (0.44) | CNR2FBP1POLBMAPT | |
| SCHEMBL10179743 | 0.72 | CES2 (0.42) | RIPK1 | |
| SCHEMBL14035562 | 0.70 | CNR2 (0.45) | CNR2RORCTSHRMAPT | |
| SCHEMBL31292359 | 0.70 | CNR2 (0.45) | CNR2FBP1RORCTSHRMAPT | |
| SCHEMBL30192734 | 0.70 | CNR2 (0.45) | CNR2RORCTSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902394-B2 | Calcilytic compounds | GLAXOSMITHKLINE LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100029782-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2120898-A1 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008077009-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029782-A1 | Calcilytic Compounds | CALCR, CALCA, CALCB | CNR2 1616/4885FBP1 395/4885RORC 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.